Drug Trial Radar · NCT03757559
A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
226
Actual
Start
Apr 15, 2013
Primary completion
Mar 8, 2014
Study completion Mar 8, 2014
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study was to evaluate the abuse potential of single doses of cebranopadol (GRT6005) relative to hydromorphone (immediate-release formulation \[IR\] and placebo in 48 non-dependent recreational opioid users. Secondary objectives were to evaluate the abuse potential of hydromorphone IR compared to placebo (trial validation), to evaluate the safety and tolerability of single doses of cebranopadol (200, 400, and 800 micrograms), and to evaluate pharmacokinetics (PK) of cebranopadol and optionally some of its metabolites.
Conditions
- Abuse, Drug
Interventions
Cebranopadol 100 microgramsDrug
Tablets were taken under fasted conditions with non-carbonated water.
Cebranopadol 400 microgramsDrug
Tablets were taken under fasted conditions with non-carbonated water.
Hydromorphone hydrochloride 4 milligramsDrug
Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
Placebo matching hydromorphoneDrug
Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
Placebo matching cebranopadolDrug
Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Drug Liking (at this moment)Time frame: At 16 distinct time points between 30 minutes and 56 hours after drug intake
Locations
1 site in 1 country. Site status is shown where the registry gives one.
INC Research
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.